Business
Caris Life Sciences Announces Another Breakthrough Study for GPSai in Identifying and Correcting Misdiagnosis of Cancer Patients
Caris Life Sciences® (NASDAQ: CAI), a leading, patient-centric, next-generation AI TechBio company and precision medicine pioneer, published a study in JAMA Network Open, titled "An AI Approach to Differentiating Lung Squamous Cell Carcinoma From Metastases of Other Origins." This study builds on the body of evidence showing the superiority of Caris' proprietary and world-leading GPSai® algorithm over traditional diagnostic procedures in correctly diagnosing cancer types.
About this update from Caris Life Sciences, Inc.
[{"type":"text","content":"Highlighting the critical role of Caris GPSai in improving cancer care","length":70,"tagName":"p","attribs":{}},{"type":"text","content":"IRVING, Texas, March 20, 2026 /PRNewswire/ -- Caris Life Sciences® (NASDAQ: CAI), a leading, patient-centric, next-generation AI TechBio company and precision medicine pioneer, published a study in JAMA Network Open, titled "An AI Approach to Differentiating Lung Squamous Cell Carcinoma From Metastases of Other Origins." This study builds on the body of evidence showing the superiority of Caris' proprietary and world-leading GPSai® algorithm over traditional diagnostic procedures in correctly diagnosing cancer types.","length":536,"tagName":"p"},{"type":"image","alt":"Caris Life Sciences Logo (PRNewsfoto/Caris Life Sciences)","displaySize":"","headline":null,"caption":"Caris Life Sciences Logo (PRNewsfoto/Caris Life Sciences)","className":"","disableSlideshowImg":false,"size":{"original":{"width":400,"height":359,"url":"https://media.zenfs.com/en/prnewswire.com/7e09703fc3526e7b3703f1e6a94d5ea8"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/DYkfDi5YhqiUCC4hCHfZpQ--/YXBwaWQ9aGlnaGxhbmRlcjt3PTcwNTtoPTYzMw--/https://media.zenfs.com/en/prnewswire.com/7e09703fc3526e7b3703f1e6a94d5ea8","width":400,"height":359}},"href":"https://mma.prnewswire.com/media/830740/Caris_Life_Sciences_Logo.html","hrefExternal":true,"rel":"nofollow"},{"type":"text","content":"This paper demonstrates that by including AI algorithms as part of routine comprehensive molecular profiling, clinicians can uncover clinically significant misdiagnoses in cases labeled as lung squamous cell carcinoma (SCC), influencing treatment decisions and patient outcomes. The study comprised 3,958 lung cancer cases submitted to Caris with a diagnosis of SCC. Caris GPSai® identified 123 of the 3,958 cases were metastases from other primary sites, including cutaneous, urothelial, head and neck and thymic cancers.","length":522,"tagName":"p"},{"type":"text","content":"The clinical impact of reclassification underscores the power of precision medicine. The study identified 88 patients (71.5%) who had guideline-preferred first-line systemic therapy change recommendations, alerting clinicians that a change in their patients' treatments would achieve better outcomes. According to the CDC website, lung SCC accounts for roughly 21...